Publications in collaboration with researchers from Centro de Investigación Médica Aplicada (25)

2023

  1. A Multimodal Scaffold for SDF1 Delivery Improves Cardiac Function in a Rat Subacute Myocardial Infarct Model

    ACS Applied Materials and Interfaces, Vol. 15, Núm. 44, pp. 50638-50651

  2. Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene

    Stem Cell Research, Vol. 71

  3. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  4. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

2022

  1. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

2021

  1. Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576

  2. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2019

  1. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  2. Immune mechanisms mediating abscopal effects in radioimmunotherapy

    Pharmacology and Therapeutics, Vol. 196, pp. 195-203

  3. Long-term results of Perioperative High Dose Rate Brachytherapy (PHDRB) and external beam radiation in adult patients with soft tissue sarcomas of the extremities and the superficial trunk: Final results of a prospective controlled study

    Radiotherapy and Oncology, Vol. 135, pp. 91-99

  4. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

  5. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  3. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain

    Cancer Immunology, Immunotherapy

  4. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2017

  1. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  2. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion

    Scientific Reports, Vol. 6